The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (10.526%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.00
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Lapse of Offer

15 Jun 2023 16:35

RNS Number : 8985C
AOP Health International Management
15 June 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

FOR IMMEDIATE RELEASE.

15 June 2023

MANDATORY CASH OFFER

 

for

SHIELD THERAPEUTICS PLC("SHIELD")

by

AOP HEALTH INTERNATIONAL MANAGEMENT AG("AOP")

LAPSE OF OFFER

1. Introduction

On 4 May 2023, AOP announced its intention to make a mandatory cash offer for all of the issued and to be issued Shield Shares not already held by AOP (the "Mandatory Offer"). On 25 May 2023, AOP published and sent the offer document containing the full terms and conditions of the unrecommended Mandatory Offer (the "Offer Document") to Shield Shareholders.

Capitalised terms used but not defined in this announcement have the same meaning given to them in the Offer Document. All references to times in this announcement are to London times, unless otherwise stated.

2. Level of acceptances

In accordance with Rule 31.7 of the Code, AOP announces that, as at 1.00 p.m. on 15 June 2023, AOP had received valid acceptances of the Mandatory Offer in respect of a total of 2,395,333 Shield Shares, representing approximately 0.33 per cent. of the issued share capital of Shield, which AOP may count towards the satisfaction of the Acceptance Condition. So far as AOP is aware, none of the acceptances have been received from persons in acting in concert with AOP.

Accordingly, AOP and persons acting in concert with it either hold, or have received valid acceptances of the Mandatory Offer in respect of, a total of 301,359,005 Shield Shares, representing approximately 42.26 per cent. of the issued share capital of Shield.

Shield Shareholders are reminded that the Mandatory Offer was conditional only upon valid acceptances of the Mandatory Offer being received (and not, where permitted, withdrawn), by no later than 1.00 p.m. today in respect of such number of Shield Shares which, together with Shield Shares acquired or agreed to be acquired by AOP or any person acting in concert with AOP at such time, would result in AOP and any person acting in concert with it, holding, in aggregate, Shield Shares carrying more than 50 per cent. of the voting rights then normally exercisable at a general meeting of Shield.

As such, the Acceptance Condition has not been satisfied and the Mandatory Offer has now lapsed. Accordingly, the Offer Period in respect of the Mandatory Offer for the purposes of the Code has now ended.

3. Interest in securities

As at 1.00 p.m. on 15 June 2023, the interests and rights to subscribe in respect of relevant securities of Shield held by AOP and persons acting in concert with AOP were as follows:

Name

Total Number of Shield Shares

Percentage of existing issued share capital of Shield

AOP

290,584,713[1]

40.75%

Dr. Christian Schweiger

11,651,713

1.63%

Dr. Günther Krumpl

1,250,000

0.17%

Michael Steiger

625,000

0.08%

As at 1.00 p.m. on 15 June 2023, and save as disclosed above, neither AOP nor, so far as AOP is aware, any person acting in concert with AOP has:

· any interest in, or right to subscribe in respect of, or any short position (whether conditional or absolute and whether in the money or otherwise) in relation to relevant securities of Shield, including any short position under a derivative, any agreement to sell or any delivery obligation or right to require another person to purchase or take delivery of relevant securities of Shield;

· any outstanding irrevocable commitment or letter of intent with respect to relevant securities of Shield; nor

· borrowed or lent any relevant securities of Shield (including any financial collateral arrangements) save for any borrowed shares which have been either on-lent or sold.

4. Further Information

As the Mandatory Offer has now lapsed, it is no longer open to acceptances and any accepting Shield Shareholders cease to be bound by their acceptances.

In the case of Shield Shares held in certificated form, the form(s) of acceptance sent to Link Group, the Receiving Agent, to accept the offer (the "Form(s) of Acceptance"), share certificate(s) and/or other document(s) of title will be returned by post (or such other method as may be approved by the Panel) within 14 days of the Mandatory Offer lapsing, to the person or agent whose name and address (outside any Restricted Jurisdiction) is set out in the Form(s) of Acceptance or, if none is set out, to the first-named or sole holder at his/her registered address (provided that no such documents will be sent to an address in a Restricted Jurisdiction).

In the case of Shield Shares held in uncertificated form, Link Group, the Receiving Agent, will, immediately (or within such longer period, not exceeding 14 days after the lapsing of the Mandatory Offer, as the Panel may approve), give instructions to Euroclear to transfer all relevant Shield Shares held in escrow balances in CREST and in relation to which it is the receiving agent for the purposes of the Mandatory Offer to the original available balances of the Shield Shareholders concerned.

The calculations in this announcement are based upon the issued share capital of Shield as at close of business on 15 June 2023 being 713,036,342 Shield Shares.

Enquiries:

AOP

Andreas Steiner (Group CEO)

Astrid Magnago (Assistant to Group CEO)

Tel: +423 220 2088

 

Numis (Financial Adviser to AOP)

Stuart Ord

Freddie Barnfield

Euan Brown

Jack McLaren

Tel: +44 (0) 20 7260 1000

 

Shield

Greg Madison (CEO)

Hans-Peter Rudolf (CFO)

 

Tel: +44 (0) 191 511 8500

 

Peel Hunt (Nominated Adviser, Financial Adviser and Joint Broker to Shield)

James Steel

Miles Cox

Oliver Duckworth

Edward Beazley

 

Tel: +44 (0) 20 7418 8900

 

finnCap Ltd (Joint Broker to Shield)

Geoff Nash

Fergus Sullivan

Alice Lane

Nigel Birks

Harriet Ward

Tel: +44 (0) 20 7220 0563

 

Further information

This Announcement is for information purposes only and is not intended to, and does not, constitute or form part of an offer, invitation or the solicitation of an offer to purchase or subscribe, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Mandatory Offer or otherwise, nor shall there be any sale, issuance or transfer of securities in Shield in any jurisdiction in contravention of applicable law.

Disclaimers

Numis Securities Limited ("Numis"), which is authorised and regulated in the UK by the Financial Conduct Authority, is acting as financial adviser to AOP, and no one else, in connection with the matters set out in this Announcement, and will not be responsible to anyone other than the board of AOP for providing the protections afforded to clients of Numis nor for providing advice in relation to the contents of this Announcement or any other matter or arrangement referred to herein. Neither Numis nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Numis in connection with this Announcement, any matter, arrangement or statement contained or referred to herein or otherwise.

Peel Hunt, which is authorised and regulated in the UK by the Financial Conduct Authority, is acting as nominated adviser, financial adviser and joint broker to Shield, and no one else, in connection with the matters set out in this Announcement, and will not be responsible to anyone other than the board of Shield for providing the protections afforded to clients of Peel Hunt nor for providing advice in relation to the contents of this Announcement or any other matter or arrangement referred to herein. Neither Peel Hunt nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Peel Hunt in connection with this Announcement, any matter, arrangement or statement contained or referred to herein or otherwise.

finnCap, which is authorised and regulated in the UK by the Financial Conduct Authority, is acting as joint broker to Shield, and no one else, in connection with the matters set out in this Announcement, and will not be responsible to anyone other than the board of Shield for providing the protections afforded to clients of finnCap or for providing advice in relation to the contents of this Announcement or any other matter or arrangement referred to herein. Neither finnCap nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of finnCap in connection with this Announcement, any matter, arrangement or statement contained or referred to herein or otherwise.

Overseas jurisdictions

The release, publication or distribution of this Announcement in jurisdictions other than the UK may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than the UK should inform themselves about, and observe, any applicable requirements. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by law, the companies and persons involved in the Mandatory Offer disclaim any responsibility or liability for the violation of such restrictions by any person. This Announcement has been prepared for the purposes of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws of jurisdictions outside of England.

Copies of this Announcement and any formal documentation relating to the Mandatory Offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction (or any jurisdiction where to do so would violate the laws of that jurisdiction) and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send it in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of the Mandatory Offer.

 


[1] AOP's total holding comprises (i) a holding of 285,436,959 (40.03 per cent.) Shield Shares, and (ii) certain warrants to subscribe for up to 5,147,754 (0.72 per cent) Shield Shares at a strike price of 6.75p and will expire on 6 January 2033.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
OUPUVAVROBUNAAR
Date   Source Headline
3rd May 20185:26 pmRNSHolding(s) in Company
2nd May 201811:00 amRNSPrice Monitoring Extension
11th Apr 20187:00 amRNSPreliminary Results for the Year Ended 31 Dec 17
6th Apr 20187:00 amRNSAppointment of Non-Executive Director
6th Apr 20187:00 amRNSResults of Pre-Submission Meeting with FDA
27th Mar 20187:00 amRNSBroadening of Feraccru indication
16th Mar 20187:00 amRNSUpdate on the AEGIS-CKD study
23rd Feb 20181:56 pmRNSReceives CHMP positive opinion on Feraccru®
22nd Feb 20187:00 amRNSBusiness and Trading Update
5th Feb 20187:00 amRNSTop-line results from Feraccru Phase III study
29th Jan 20187:00 amRNSNotice of Results
25th Jan 20187:00 amRNSGrant of share options
10th Oct 20177:00 amRNSCompletion of patient enrolment in Phase 3 study
5th Oct 20177:00 amRNSPDMR Acquisition of Shares
20th Sep 20177:00 amRNSInterim Report
14th Sep 20177:00 amRNSBoard Change
6th Sep 20177:00 amRNSUS Composition of Matter Patent Allowed
31st Aug 20177:00 amRNSShield to Present at Baird Healthcare Conference
15th Aug 20177:00 amRNSNotice of Results
11th Jul 20172:59 pmRNSGrant of Share Options
10th Jul 20174:16 pmRNSHolding(s) in Company
6th Jul 20177:00 amRNSFeraccru licence agreement for Switzerland
5th Jul 201712:38 pmRNSHolding(s) in Company
3rd Jul 201712:34 pmRNSWarrant Exercise and Expiry
28th Jun 201710:37 amRNSHolding(s) in Company
28th Jun 20178:00 amRNSAdmission of New Ordinary Shares
22nd Jun 20177:00 amRNSBiomarker data on ferric maltol in patients
15th Jun 20171:59 pmRNSResults of Fundraise
15th Jun 20177:00 amRNSProposed Fundraise
13th Jun 20172:40 pmRNSResult of AGM
26th May 20177:00 amRNSAppointment of Joint Broker
28th Apr 20177:00 amRNSAnnual Report, Accounts and AGM Notification
4th Apr 20177:00 amRNSAppointment of Chief Financial Officer
4th Apr 20177:00 amRNSPreliminary Results for the Year Ended 31 Dec 2016
13th Mar 20177:00 amRNSNotice of Results
13th Mar 20177:00 amRNSIP Portfolio Update
30th Jan 201710:50 amRNSDirectorate and Secretarial Update
6th Jan 20177:00 amRNSBusiness Update
7th Nov 20167:00 amRNSBoard Change
20th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
13th Sep 20169:25 amRNSGrant of Share Awards
7th Sep 20167:37 amRNSComposition of Matter Patent Granted on Feraccru®
7th Sep 20167:00 amRNSComposition of Matter Patent Granted on Feraccru®
15th Aug 201612:22 pmRNSNotice of Results
4th Aug 201611:05 amRNSResult of AGM
1st Aug 201612:00 pmRNSPresenting at Canaccord Genuity Conference, Boston
30th Jun 20165:06 pmRNS2015 Annual Report and Accounts and Notice of AGM
14th Jun 20167:00 amRNSMaiden Preliminary Results for FY15
23rd Mar 20167:00 amRNSNotice of results and change of accounting date
11th Mar 20167:00 amRNSGrant of Share Awards

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.